Clinical research company IQVIA (NYSE: IQV) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 8.7% year on year to $4.37 billion. The company’s full-year revenue guidance of $17.38 billion at the midpoint came in 0.5% above analysts’ estimates. Its non-GAAP profit of $3.15 per share was 3.9% above analysts’ consensus estimates.

Is now the time to buy IQV? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

IQVIA’s second quarter was characterized by broad-based growth and accelerating demand across its clinical and commercial businesses, with market participants responding positively to the results. CEO Ari Bousbib attributed the strong performance to improved operational execution and a healthier demand environment, highlighting a 6% organic growth rate—triple that of last year. Management also cited strong net new bookings and increasing win rates, particularly in the R&D segment, as contributing factors to the quarter’s outperformance.

Looking ahead, IQVIA’s updated guidance is driven by continued strength in both clinical trial demand and commercial solutions, as well as increasing adoption of AI-driven offerings. Management emphasized that investments in proprietary data, domain knowledge, and compliance expertise are expected to further differentiate the company in a competitive landscape. CFO Michael J. Fedock stated, “Our operational productivity programs are delivering incremental margin value, while strong booking trends support momentum into next year.”

Key Insights from Management’s Remarks

Management credited the quarter’s growth to robust client demand, continued AI integration, and expanding partnerships with both large pharmaceutical companies and emerging biopharma clients.

• R&D bookings momentum: Net new bookings in the R&D Solutions business grew 19% year-over-year, with a book-to-bill ratio of 1.22, signaling sustained demand from both large pharma and emerging biopharma (EBP) customers.
• Commercial solutions acceleration: Organic growth in commercial solutions reached 5%, driven by a surge in new drug launches and expanded client use of analytics, consulting, and patient engagement services. Management noted that large pharma clients are increasingly outsourcing full commercialization of select therapies.
• AI-driven differentiation: IQVIA’s artificial intelligence capabilities are being widely adopted, with 294 AI agents now deployed across 90 use cases. AI is enhancing study design, patient recruitment, and operational efficiency, which has contributed to higher win rates and competitive displacements of incumbents.
• Operational productivity gains: The company achieved 90 basis points of operational margin improvement in the quarter, largely attributed to productivity initiatives and AI-driven efficiencies, partially offset by non-operational headwinds such as pass-through costs.
• Strategic M&A expansion: Completion of the Charles River discovery assets acquisition contributed to segment growth and broadened the company’s service offerings, particularly in early-stage development.

Drivers of Future Performance

IQVIA’s outlook is anchored by continued demand for outsourced clinical and commercial services, supported by AI capabilities and a robust pipeline of new business.

• Rising outsourcing trends: Management expects increasing outsourcing from large pharmaceutical clients, especially as AI accelerates drug discovery and development. Customers are requesting greater capacity, with some projecting a doubling of their study portfolios, which could drive long-term growth.
• AI integration as a growth lever: Proprietary healthcare data, deep domain expertise, and regulatory compliance position IQVIA to co-develop AI solutions with top pharma clients. These partnerships are viewed as key to sustaining competitive advantage and winning future business.
• Margin management amid headwinds: While operational productivity and AI investments are expected to boost margins, management highlighted pass-through costs and lower-margin M&A as ongoing headwinds. Maintaining flat margins is a priority despite these challenges, with future improvements tied to further operational gains and business mix shifts.

Catalysts in Upcoming Quarters

In the coming quarters, our analysts will monitor (1) the pace of new bookings and backlog quality in R&D Solutions, (2) further adoption and monetization of AI-enabled offerings across both clinical and commercial segments, and (3) integration of recent acquisitions like the Charles River assets. Progress on operational productivity programs and clarity on potential adjustments to inactive trials in the backlog will also be important to track.

IQVIA currently trades at $241.05, up from $213.22 just before the earnings. Is there an opportunity in the stock? Find out in our full research report (it’s free).

Stocks That Trumped Tariffs

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.